Anesthesia Pharmacology Chapter 25: Pulmonary Pharmacology Practice Questions

Drug(s) that may be useful in treating pulmonary hypertension (PAH):
1. Prostacyclin
2. Prostacyclin analogs
3. Both
4. Neither
Drug class/classes that may be useful in treating pulmonary hypertension:
1. Phosphodiesterase-5 inhibitors
2. A guanylyl cyclase stimulator
3. Endothelin receptor blockers
4. A & B
5. B & C
6. A & C
7. A, B & C
Concerning pulmonary hypertension:
1. Platelet activation and endothelial dysfunction in PAH induce decreases in prostacyclin levels and increases in thromboxane A2 production.
2. Prostacyclin (PGI2) promotes vasodilation through activation of cAMP requiring pathways.
3. Prostacyclin synthase levels are increased in pulmonary arteries of patients exhibiting pulmonary hypertension.
4. A & B
5. B & C
6. A & C
7. A, B & C
Imbalance of mediators important in pulmonary artery pathologies associated with pulmonary artery hypertension can be managed by administration of prostanoids.
1. True
2. False
First prostanoid available for management of pulmonary hypertension:
1. Treprostinil (Remodulin; Tyvaso)
2. Epoprostenol (Flolan; Veletri)
Continuous IV infusion of epoprostenol:
1. Improved pulmonary hypertension survival
2. Improved functional capacity
3. Both
4. Neither
Characteristic(s) of the treprostinil compared to epoprostenol:
1. Treprostinil exhibits a shorter half-life
2. Treprostinil can be administered by continuous subcutaneous in IV administration.
3. Both
4. Neither
Inhaled Prostacyclins:
1. Comparable beneficial effects compared with infused prostacyclin treatment.
2. Elimination ofside effects associated with infusion catheters
3. Both
4. Neither
Examples/example of Prostacyclins approved for treating pulmonary hypertension:
1. Trepostinil
2. Iloprost (Ventavis)
3. Both
4. Neither
Adding a PDE5 (phosphodiesterase-5) inhibitor to a regimen including an inhaled prostacyclin can result in which one(s) of the following?
1. Improved pulmonary hemodynamics compared to prostanoids alone.
2. Improved pulmonary functional capacity available with prostanoids alone
3. Both
4. Neither